Lyell Immunopharma, Inc.
LYEL$129M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSOUTH SAN FRANCISCO300 employees
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
7wMarket Overview
Stock performance and key metrics
LYEL News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
rondecabtagene autoleucel
Large B-cell Lymphoma
LYL314
Relapsed Non-Hodgkin Lymphoma
LYL273
Colorectal Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
rondecabtagene autoleucel | Phase 3 | Large B-cell Lymphoma | - | - |
LYL314 | Phase 2 | Relapsed Non-Hodgkin Lymphoma | - | - |
LYL273 | Phase 2 | Colorectal Cancer | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply